Drug Approval | November 23, 2025
Biocon Pharma gets FDA nod for arthritis drug Tofacitinib ER
Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis
Tofacitinib extended-release tablets are a Janus kinase inhibitor indicated for Rheumatoid Arthritis
The company says the innovation delivers stronger moisture protection for highly sensitive drug molecules
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy
HER2-mutant NSCLC typically has a poor prognosis and limited treatment options
Exemplifies commitment of Merck to energy efficiency and sustainable practices in high-performance computing by featuring advanced water-cooling systems and a hybrid cloud infrastructure
Innovent plans to soon submit a new drug application (NDA) to China’s National Medical Products Administration
The collaboration to develop breakthrough myeloid cell engagers (MCEs) signals a bold push into a promising new frontier in cancer therapy
The formulation is backed by over 80 clinical trials and 200 scientific publications
The licence covers Actimed’s existing patents, its proprietary know-how and any future related patents, giving Mankind full control to advance the products under its own brands
Subscribe To Our Newsletter & Stay Updated
